NOD mice treated with anti-PD-L1 or anti-PD-1 antibodies develop rapid diabetes associated with increased CD8+ T cell proliferation (Ansari et al., 2003; Pauken et al., 2013). This evidence concerns the gene CD8A and diabetes mellitus.